1. Comparison of Oral Tolerance to ApoB and HSP60 Peptides in Preventing Atherosclerosis Lesion Formation in Apob48−/Ldlr− Mice
- Author
-
Vijay V. Kakkar, Vrushali Deshpande, Sonia Samson, T. S. Sneha, Sagar Tarate, Rupak Mukhopadhyay, Meenakshi Varma, Xinjie Lu, and Lakshmi Mundkur
- Subjects
medicine.medical_specialty ,Apolipoprotein B ,biology ,Lesion ,chemistry.chemical_compound ,Interleukin 10 ,Endocrinology ,chemistry ,Oral administration ,Heat shock protein ,Low-density lipoprotein ,Internal medicine ,LDL receptor ,Immunology ,biology.protein ,medicine ,lipids (amino acids, peptides, and proteins) ,HSP60 ,medicine.symptom - Abstract
Antigen-specific immune modulation is emerging as an attractive therapeutic option to prevent atherosclerosis. We compared the efficacy of oral administration of peptides derived from apolipoprotein B (ApoB; 661–680) and heat shock protein 60 (HSP60; 153–163), in the prevention of atherosclerotic lesion formation hyperlipidemic low density lipoprotein receptordeficient (LDLr−/−), apolipoprotein B-100 only (apoB100/100) mice model. Oral administration of peptides induced tolerance as seen by an increase in regulatory T cells in the peripheral immune system. Tolerance to ApoB peptide reduced plaque development by 28.7% (P<0.001) while HSP60 was effective in reducing lesion development by 26.8% in ApoB48/LDLr−/− mice. While tolerance to HSP60 resulted in increase in anti-inflammatory cytokines (IL10 and TGF-β), ApoB tolerance was effective in reducing the lipid deposition in the lesion. Our results suggest that the two peptides have distinct mechanisms of controlling the development of atherosclerosis in mice.
- Published
- 2013
- Full Text
- View/download PDF